Company Information: Astellas Pharma Inc.<\/p>\n","protected":false},"featured_media":0,"template":"","meta":{"Ticker":"4503","DATE":"2025-12-19","longName":"Astellas Pharma Inc.","company_name_ja":"\u30a2\u30b9\u30c6\u30e9\u30b9\u88fd\u85ac(\u682a)","fullTimeEmployees":14099,"address":"","phone":"","website":"https:\/\/www.astellas.com","industry":"Drug Manufacturers - General","sector":"Healthcare","regularMarketPrice":2100,"financialCurrency":"","marketCap":3761553,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":162.22,"epsForward":0,"bookValue":0,"totalRevenue":2139245000000,"OperatingIncome":380059000000,"operatingMargins":17.77,"NetIncome":291535000000,"profitMargins":13.630000000000001,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":15.94,"recommendationMean":2.4615399999999998,"recommendationKey":"buy","targetMeanPrice":2388.4614000000001,"numberOfAnalystOpinions":14,"analyst_earnings_data":"{\"success\": true, \"fetched_at\": \"2026-08-01T05:01:09.064924\", \"ticker\": \"4503\", \"ticker_full\": \"4503.T\", \"company_name\": \"ASTELLAS PHARMA\", \"analyst_recommendations\": {\"has_data\": true, \"period\": \"3\", \"strong_buy\": 0, \"buy\": 4, \"hold\": 9, \"sell\": 0, \"strong_sell\": 1, \"total_analysts\": 14, \"recommendation_key\": \"buy\", \"recommendation_mean\": 2.46154}, \"target_prices\": {\"has_data\": true, \"current\": 2202.0, \"high\": 3000.0, \"low\": 1700.0, \"mean\": 2388.4614, \"median\": 2400.0}, \"earnings_dates\": {\"has_data\": true, \"next_earnings\": {\"date\": \"2026-08-05\", \"eps_estimate\": 18.1, \"eps_actual\": null, \"surprise_pct\": null}, \"future_count\": 1, \"past_earnings\": [{\"date\": \"2026-04-27\", \"eps_estimate\": 21.44, \"eps_actual\": 24.29, \"surprise_pct\": 13.31}, {\"date\": \"2026-02-04\", \"eps_estimate\": 42.44, \"eps_actual\": 56.04, \"surprise_pct\": 32.03}, {\"date\": \"2025-10-29\", \"eps_estimate\": 28.86, \"eps_actual\": 44.22, \"surprise_pct\": 53.25}, {\"date\": \"2025-07-30\", \"eps_estimate\": 18.1, \"eps_actual\": 38.22, \"surprise_pct\": 111.21}, {\"date\": \"2025-04-25\", \"eps_estimate\": 4.3, \"eps_actual\": 41.84, \"surprise_pct\": 873.37}]}, \"shareholders\": {\"has_data\": true, \"insider_pct\": 1.34, \"institution_pct\": 60.84, \"major_holders\": [{\"label\": \"\", \"value\": 1.34}, {\"label\": \"\", \"value\": 60.84}, {\"label\": \"\", \"value\": 61.67}, {\"label\": \"\", \"value\": 426.0}], \"institutional_holders\": [{\"holder\": \"Pacer Advisors, Inc.\", \"shares\": 2142128, \"date_reported\": \"2026-03-31\", \"pct_held\": 0.12, \"pct_change\": 9.6, \"value\": 4716965856}, {\"holder\": \"Paradigm Asset Management Company, LLC\", \"shares\": 5100, \"date_reported\": \"2026-03-31\", \"pct_held\": 0.0, \"pct_change\": 0.0, \"value\": 11230200}], \"mutualfund_holders\": [{\"holder\": \"VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund\", \"shares\": 26153361, \"date_reported\": \"2026-04-30\", \"pct_held\": 1.45, \"pct_change\": -0.11, \"value\": 57589700922}, {\"holder\": \"VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund\", \"shares\": 17301438, \"date_reported\": \"2026-03-31\", \"pct_held\": 0.96, \"pct_change\": 2.32, \"value\": 38097766476}, {\"holder\": \"iShares Trust-iShares Core MSCI EAFE ETF\", \"shares\": 12833300, \"date_reported\": \"2026-06-30\", \"pct_held\": 0.71, \"pct_change\": 0.0, \"value\": 28258926600}, {\"holder\": \"iShares, Inc.-iShares MSCI Japan ETF\", \"shares\": 7414750, \"date_reported\": \"2026-06-30\", \"pct_held\": 0.41, \"pct_change\": 0.59, \"value\": 16327279500}, {\"holder\": \"Fidelity Concord Street Trust-Fidelity International Index Fund\", \"shares\": 6619571, \"date_reported\": \"2026-06-30\", \"pct_held\": 0.37, \"pct_change\": -2.79, \"value\": 14576295342}, {\"holder\": \"iShares Trust-iShares MSCI EAFE ETF\", \"shares\": 6281550, \"date_reported\": \"2026-06-30\", \"pct_held\": 0.35, \"pct_change\": -0.77, \"value\": 13831973100}, {\"holder\": \"Fidelity Salem Street TRT-Fidelity SAI Intl Low Volatility Index Fd.\", \"shares\": 5929200, \"date_reported\": \"2026-06-30\", \"pct_held\": 0.33, \"pct_change\": 3.18, \"value\": 13056098400}, {\"holder\": \"J.P. Morgan Exchange-Traded Fund Trust-JPMorgan BetaBuilders Japan ETF\", \"shares\": 5741200, \"date_reported\": \"2026-04-30\", \"pct_held\": 0.32, \"pct_change\": 8.85, \"value\": 12642122400}, {\"holder\": \"AQR Funds-AQR Long-Short Equity Fund\", \"shares\": 5220000, \"date_reported\": \"2026-03-31\", \"pct_held\": 0.29, \"pct_change\": 18.99, \"value\": 11494440000}, {\"holder\": \"Fidelity Covington Trust-Fidelity Enhanced International ETF\", \"shares\": 4621229, \"date_reported\": \"2026-06-30\", \"pct_held\": 0.26, \"pct_change\": 7.45, \"value\": 10175946258}]}}","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"Astellas Pharma Inc. engages in the research, development, manufacture, sale, and supply of pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia; VYLOY, a treatment for gastric adenocarcinoma and esophagogastric junction adenocarcinoma; and PADCEV, a treatment for patients with metastatic urothelial carcinoma. It also provides VEOZAH, a treatment for vasomotor symptoms associated with menopause; IZERVAY, a treatment for age-related macular degeneration with geographic atrophy; Betanis\/Myrabetriq\/BETMIGA, a treatment for overactive bladder; and Prograf, an immunosuppressant. It offers its products to oncology, ophthalmology, urology, immunology, and women's health areas. The company was formerly known as Yamanouchi Pharmaceutical Co. Ltd. and changed its name to Astellas Pharma Inc. in April 2005. Astellas Pharma Inc. was founded in 1923 and is headquartered in Chuo, Japan.","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":39,"get_dividend_history_year2":76,"get_dividend_history_year3":72,"get_dividend_history_year4":65,"get_dividend_history_year5":55,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"financial_data":"","detailed_financial_data":"{\"success\": true, \"fetched_at\": \"2026-08-09T03:24:25.825754\", \"ticker\": \"4503\", \"ticker_full\": \"4503.T\", \"company_name\": \"ASTELLAS PHARMA\", \"company_info\": {\"name_en\": \"ASTELLAS PHARMA\", \"long_name\": \"Astellas Pharma Inc.\", \"sector\": \"Healthcare\", \"industry\": \"Drug Manufacturers - General\", \"website\": \"https:\/\/www.astellas.com\", \"employees\": 14099, \"country\": \"Japan\", \"city\": \"Chuo\", \"address\": \"2-5-1, Nihonbashi-Honcho\", \"description\": \"Astellas Pharma Inc. engages in the research, development, manufacture, sale, and supply of pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia; VYLOY, a treatment for gastric adenocarcinoma and esophagogastric junction adenocarcinoma; and PADCEV, a treatment for patients with metastatic urothelial carcinoma. It also provides VEOZAH, a treatment for vasomotor symptoms associated with menopause; IZERVAY, a treatment for age-related macular degeneration with geographic atrophy; Betanis\/Myrabetriq\/BETMIGA, a treatment for overactive bladder; and Prograf, an immunosuppressant. It offers its products to oncology, ophthalmology, urology, immunology, and women's health areas. The company was formerly known as Yamanouchi Pharmaceutical Co. Ltd. and changed its name to Astellas Pharma Inc. in April 2005. Astellas Pharma Inc. was founded in 1923 and is headquartered in Chuo, Japan.\"}, \"price_trend\": {\"ma_5\": {\"ma_value\": 2223.8, \"deviation\": 4.64, \"trend\": \"up\"}, \"ma_25\": {\"ma_value\": 2188.6, \"deviation\": 6.32, \"trend\": \"up\"}, \"ma_75\": {\"ma_value\": 2224.31, \"deviation\": 4.62, \"trend\": \"up\"}, \"ma_200\": {\"ma_value\": 2179.23, \"deviation\": 6.78, \"trend\": \"up\"}}, \"financials\": {\"years\": [{\"year\": 2026, \"revenue\": 2139245000000.0, \"revenue_fmt\": \"\u00a52.1T\", \"gross_profit\": 1730820000000.0, \"gross_profit_fmt\": \"\u00a51.7T\", \"operating_income\": 380059000000.0, \"operating_income_fmt\": \"\u00a53801\u5104\", \"ebit\": 390659000000.0, \"ebit_fmt\": \"\u00a53907\u5104\", \"net_income\": 291535000000.0, \"net_income_fmt\": \"\u00a52915\u5104\", \"eps\": 162.22, \"operating_margin\": 17.77, \"total_assets\": 3567042000000.0, \"total_assets_fmt\": \"\u00a53.6T\", \"total_equity\": 1829044000000.0, \"total_equity_fmt\": \"\u00a51.8T\", \"total_debt\": 565952000000.0, \"total_debt_fmt\": \"\u00a55660\u5104\", \"total_cash\": 281605000000.0, \"total_cash_fmt\": \"\u00a52816\u5104\", \"equity_ratio\": 51.28, \"de_ratio\": 0.31, \"current_ratio\": 1.17, \"operating_cf\": 560188000000.0, \"operating_cf_fmt\": \"\u00a55602\u5104\", \"investing_cf\": -66722000000.0, \"investing_cf_fmt\": \"-\u00a5667\u5104\", \"financing_cf\": -404779000000.0, \"financing_cf_fmt\": \"-\u00a54048\u5104\", \"free_cf\": 475543000000.0, \"free_cf_fmt\": \"\u00a54755\u5104\", \"net_margin\": 13.63, \"roe\": 15.94, \"roa\": 8.17}, {\"year\": 2025, \"revenue\": 1912323000000.0, \"revenue_fmt\": \"\u00a51.9T\", \"gross_profit\": 1563117000000.0, \"gross_profit_fmt\": \"\u00a51.6T\", \"operating_income\": 40248000000.0, \"operating_income_fmt\": \"\u00a5402\u5104\", \"ebit\": 48914000000.0, \"ebit_fmt\": \"\u00a5489\u5104\", \"net_income\": 50747000000.0, \"net_income_fmt\": \"\u00a5507\u5104\", \"eps\": 28.24, \"operating_margin\": 2.1, \"total_assets\": 3339544000000.0, \"total_assets_fmt\": \"\u00a53.3T\", \"total_equity\": 1513255000000.0, \"total_equity_fmt\": \"\u00a51.5T\", \"total_debt\": 831426000000.0, \"total_debt_fmt\": \"\u00a58314\u5104\", \"total_cash\": 188372000000.0, \"total_cash_fmt\": \"\u00a51884\u5104\", \"equity_ratio\": 45.31, \"de_ratio\": 0.55, \"current_ratio\": 1.13, \"operating_cf\": 194512000000.0, \"operating_cf_fmt\": \"\u00a51945\u5104\", \"investing_cf\": -89419000000.0, \"investing_cf_fmt\": \"-\u00a5894\u5104\", \"financing_cf\": -261367000000.0, \"financing_cf_fmt\": \"-\u00a52614\u5104\", \"free_cf\": 137182000000.0, \"free_cf_fmt\": \"\u00a51372\u5104\", \"net_margin\": 2.65, \"roe\": 3.35, \"roa\": 1.52}, {\"year\": 2024, \"revenue\": 1603672000000.0, \"revenue_fmt\": \"\u00a51.6T\", \"gross_profit\": 1311187000000.0, \"gross_profit_fmt\": \"\u00a51.3T\", \"operating_income\": 18947000000.0, \"operating_income_fmt\": \"\u00a5189\u5104\", \"ebit\": 36974000000.0, \"ebit_fmt\": \"\u00a5370\u5104\", \"net_income\": 17045000000.0, \"net_income_fmt\": \"\u00a5170\u5104\", \"eps\": 9.47, \"operating_margin\": 1.18, \"total_assets\": 3569603000000.0, \"total_assets_fmt\": \"\u00a53.6T\", \"total_equity\": 1595988000000.0, \"total_equity_fmt\": \"\u00a51.6T\", \"total_debt\": 920016000000.0, \"total_debt_fmt\": \"\u00a59200\u5104\", \"total_cash\": 335687000000.0, \"total_cash_fmt\": \"\u00a53357\u5104\", \"equity_ratio\": 44.71, \"de_ratio\": 0.58, \"current_ratio\": 0.93, \"operating_cf\": 172475000000.0, \"operating_cf_fmt\": \"\u00a51725\u5104\", \"investing_cf\": -845802000000.0, \"investing_cf_fmt\": \"-\u00a58458\u5104\", \"financing_cf\": 614060000000.0, \"financing_cf_fmt\": \"\u00a56141\u5104\", \"free_cf\": 89978000000.0, \"free_cf_fmt\": \"\u00a5900\u5104\", \"net_margin\": 1.06, \"roe\": 1.07, \"roa\": 0.48}, {\"year\": 2023, \"revenue\": 1518619000000.0, \"revenue_fmt\": \"\u00a51.5T\", \"gross_profit\": 1230266000000.0, \"gross_profit_fmt\": \"\u00a51.2T\", \"operating_income\": 131557000000.0, \"operating_income_fmt\": \"\u00a51316\u5104\", \"ebit\": 141140000000.0, \"ebit_fmt\": \"\u00a51411\u5104\", \"net_income\": 98714000000.0, \"net_income_fmt\": \"\u00a5987\u5104\", \"eps\": 54.09, \"operating_margin\": 8.66, \"total_assets\": 2456518000000.0, \"total_assets_fmt\": \"\u00a52.5T\", \"total_equity\": 1507954000000.0, \"total_equity_fmt\": \"\u00a51.5T\", \"total_debt\": 125000000000.0, \"total_debt_fmt\": \"\u00a51250\u5104\", \"total_cash\": 376840000000.0, \"total_cash_fmt\": \"\u00a53768\u5104\", \"equity_ratio\": 61.39, \"de_ratio\": 0.08, \"current_ratio\": 1.45, \"operating_cf\": 327767000000.0, \"operating_cf_fmt\": \"\u00a53278\u5104\", \"investing_cf\": -84500000000.0, \"investing_cf_fmt\": \"-\u00a5845\u5104\", \"financing_cf\": -195623000000.0, \"financing_cf_fmt\": \"-\u00a51956\u5104\", \"free_cf\": 239226000000.0, \"free_cf_fmt\": \"\u00a52392\u5104\", \"net_margin\": 6.5, \"roe\": 6.55, \"roa\": 4.02}], \"has_data\": true}, \"dividends\": {\"history\": [{\"year\": 2022, \"amount\": 55.0}, {\"year\": 2023, \"amount\": 65.0}, {\"year\": 2024, \"amount\": 72.0}, {\"year\": 2025, \"amount\": 76.0}, {\"year\": 2026, \"amount\": 39.0}], \"latest\": 39.0, \"has_data\": true}}","ma_5_value":0,"ma_5_deviation":0,"ma_5_trend":"","ma_25_value":0,"ma_25_deviation":0,"ma_25_trend":"","ma_75_value":0,"ma_75_deviation":0,"ma_75_trend":"","ma_200_value":0,"ma_200_deviation":0,"ma_200_trend":"","previousClose":0,"open":0,"dayHigh":0,"dayLow":0,"volume":0,"averageVolume":0,"revenueGrowth":0},"sector":[],"class_list":["post-6911","company","type-company","status-publish","hentry"],"yoast_head":"\n